KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Accumulated Expenses (2016 - 2026)

West Pharmaceutical Services has reported Accumulated Expenses over the past 18 years, most recently at $46.6 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 31.27% to $46.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $46.6 million through Mar 2026, down 31.27% year-over-year, with the annual reading at $39.2 million for FY2025, 46.67% down from the prior year.
  • Accumulated Expenses was $46.6 million for Q1 2026 at West Pharmaceutical Services, up from $39.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $111.8 million in Q3 2025 and troughed at $39.2 million in Q4 2025.
  • The 5-year median for Accumulated Expenses is $78.1 million (2022), against an average of $77.6 million.
  • Peak annual rise in Accumulated Expenses hit 40.45% in 2025, while the deepest fall reached 46.67% in 2025.
  • Tracing WST's Accumulated Expenses over 5 years: stood at $76.8 million in 2022, then skyrocketed by 37.89% to $105.9 million in 2023, then tumbled by 30.59% to $73.5 million in 2024, then plummeted by 46.67% to $39.2 million in 2025, then increased by 18.88% to $46.6 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $46.6 million, $39.2 million, and $111.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.